MAPK7 and breast carcinoma: For instance, and among others, ERK5 pathway is associated with increased metastatic activity in prostate [21] and hepatocarcinoma [19] cancers, to elevated growth of breast cancer cells, overexpressing the ErbB2/Her2 receptor [22] or to chemoresistance of breast cancer [23] or acute myeloid leukemia cells [24].